40 related articles for article (PubMed ID: 38484212)
21. Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients With Cancer.
Kehl KL; Schrag D; Hassett MJ; Uno H
JAMA Netw Open; 2020 Jun; 3(6):e206976. PubMed ID: 32511717
[TBL] [Abstract][Full Text] [Related]
22. Project GENIE Announces Biopharma Collaboration.
Cancer Discov; 2020 Feb; 10(2):OF2. PubMed ID: 31907168
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports.
Kehl KL; Elmarakeby H; Nishino M; Van Allen EM; Lepisto EM; Hassett MJ; Johnson BE; Schrag D
JAMA Oncol; 2019 Oct; 5(10):1421-1429. PubMed ID: 31343664
[TBL] [Abstract][Full Text] [Related]
24. Transformation model estimation of survival under dependent truncation and independent censoring.
Chiou SH; Austin MD; Qian J; Betensky RA
Stat Methods Med Res; 2019 Dec; 28(12):3785-3798. PubMed ID: 30543153
[TBL] [Abstract][Full Text] [Related]
25. AACR Project GENIE: Powering Precision Medicine through an International Consortium.
AACR Project GENIE Consortium
Cancer Discov; 2017 Aug; 7(8):818-831. PubMed ID: 28572459
[TBL] [Abstract][Full Text] [Related]
26. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.
Lochhead P; Kuchiba A; Imamura Y; Liao X; Yamauchi M; Nishihara R; Qian ZR; Morikawa T; Shen J; Meyerhardt JA; Fuchs CS; Ogino S
J Natl Cancer Inst; 2013 Aug; 105(15):1151-6. PubMed ID: 23878352
[TBL] [Abstract][Full Text] [Related]
27. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
[TBL] [Abstract][Full Text] [Related]
28. TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier M; Hollstein M; Hainaut P
Cold Spring Harb Perspect Biol; 2010 Jan; 2(1):a001008. PubMed ID: 20182602
[TBL] [Abstract][Full Text] [Related]
29. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing.
Herreros-Villanueva M; Bujanda L; Ruiz-Rebollo L; Torremocha R; Ramos R; Martín R; Artigas MC
Gastroenterol Hepatol; 2022 Oct; 45(8):637-644. PubMed ID: 35092761
[TBL] [Abstract][Full Text] [Related]
31. Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set.
Kehl KL; Lavery JA; Brown S; Fuchs H; Riely G; Schrag D; Newcomb A; Nichols C; Micheel CM; Bedard PL; Sweeney SM; Fiandalo M; Panageas KS;
JCO Precis Oncol; 2024 Mar; 8():e2300489. PubMed ID: 38484212
[TBL] [Abstract][Full Text] [Related]
32. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.
Loong HH; Shimizu T; Prawira A; Tan AC; Tran B; Day D; Tan DSP; Ting FIL; Chiu JW; Hui M; Wilson MK; Prasongsook N; Koyama T; Reungwetwattana T; Tan TJ; Heong V; Voon PJ; Park S; Tan IB; Chan SL; Tan DSW
ESMO Open; 2023 Aug; 8(4):101586. PubMed ID: 37356359
[TBL] [Abstract][Full Text] [Related]
33. Understanding next generation sequencing in oncology: A guide for oncologists.
Moorcraft SY; Gonzalez D; Walker BA
Crit Rev Oncol Hematol; 2015 Dec; 96(3):463-74. PubMed ID: 26160606
[TBL] [Abstract][Full Text] [Related]
34. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
Kruglyak KM; Lin E; Ong FS
Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
[TBL] [Abstract][Full Text] [Related]
35. Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.
Malapelle U; Donne AD; Pagni F; Fraggetta F; Rocco EG; Pasello G; Perrone G; Pepe F; Vatrano S; Pignata S; Pinto C; Pruneri G; Russo A; Soto Parra HJ; Vallone S; Marchetti A; Troncone G; Novello S
Crit Rev Oncol Hematol; 2024 Jan; 193():104217. PubMed ID: 38040072
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
